Reducing the risk of gastroduodenal ulcers with a fixed combination of esomeprazole and low-dose acetyl salicylic acid

References

• Trinder P, Rajaratnam G, Lewis M, Croft P. Prophylactic aspirin use in the adult general population. J. Public Health Med.25(4), 377–380 (2003).
   PubMedGoogle Scholar
• Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet373, 1849–1860 (2009).
   PubMed Web of Science ®Google Scholar
• Antithrombotic trialists’ collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J.324(7329), 71–86 (2002).
   PubMed Web of Science ®Google Scholar
• Hart J, Hawkey CJ, Lanas A et al. Predictors of gastroduodenal erosions in patients taking low-dose aspirin. Aliment. Pharmacol. Ther.31, 143–149 (2010).
   PubMed Web of Science ®Google Scholar
• Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology117, 17–25 (1999).
   PubMed Web of Science ®Google Scholar
• Yeomans ND, Lanas AI, Talley NJ et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment. Pharmacol. Ther.22, 795–801 (2005).
   PubMed Web of Science ®Google Scholar
• Yeomans ND, Lanas A, Labenz J et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am. J. Gastroenterol.103, 2465–2473 (2008).
   PubMed Web of Science ®Google Scholar
• Scheiman JM, Devereaux PJ, Herlitz J et al. Prevention of peptic ulcer with esomeprazole in cardiovascular risk patients treated with low-dose acetylsalicylic acid at risk for ulcer development: a randomised, controlled trial (OBERON). Heart97, 797–802 (2011).
   PubMed Web of Science ®Google Scholar
• No authors listed. A randomised, blinded, trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). CAPRIE Steering Committee. Lancet348, 1329–1339 (1996).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med.345, 494–502 (2001).
   PubMed Web of Science ®Google Scholar
• Patrono C. Aspirin: new cardiovascular uses for an old drug. Am. J. Med.110(Suppl. 1A), 62S–65S (2001).
   PubMedGoogle Scholar
• Serrano P, Lanas A, Arroyo MT, Ferreira IJ. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment. Pharmacol. Ther.16(11), 1945–1953 (2002).
   PubMed Web of Science ®Google Scholar
• Lai KC, Lam SK, Chu KM et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med.346(26), 2033–2038 (2002).
   PubMed Web of Science ®Google Scholar
• Lanas A. Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice. Expert Opin. Drug Saf.10(1), 45–54 (2010).
   PubMedGoogle Scholar
• Brodie DA, Chase BJ. Role of gastric acid in aspirin-induced gastric irritation in the rat. Gastroenterology53, 604–610 (1967).
   PubMed Web of Science ®Google Scholar
• Elliott SL, Ferris RJ, Giraud AS, Skeljo MV, Yeomans ND. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin. Exper. Pharmacol. Physiol.23, 432–434 (1996).
   PubMed Web of Science ®Google Scholar
• Daneshmend TK, Stein AG, Bhaskar NK, Hawkey CJ. Abolition by omeprazole of aspirin induced gastric mucosal injury in man. Gut31, 514–517 (1990).
   PubMed Web of Science ®Google Scholar
• Küster LJ, Frölich JC. Platelet aggregation and thromboxane release induced by arachidonic acid, collagen, ADP and platelet-activating factor following low dose acetylsalicylic acid in man. Prostaglandins32(3), 415–423 (1986).
   PubMed Web of Science ®Google Scholar
• Sachar CL. The pharmacology of esomeprazole and its role in gastric acid related diseases. Expert Opin. Drug Metab. Toxicol.5(9), 1113–1124 (2009).
   PubMedGoogle Scholar
• Röhss K, Wilder-Smith C, Nauclér E, Jansson L. Esomeprazole 20 mg provides more effective intragastric acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin. Drug Invest.24(1), 1–7 (2003).
   Google Scholar
• Thiessen JJ. Aspirin: plasma concentration and effects. Thromb. Res. Suppl.4, 105–111 (1983).
   PubMed Web of Science ®Google Scholar
• Abelo A, Andersson T, Antonsson M, Naudot A, Skanberg I, Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug. Metab. Dispos.28, 966–972 (2000).
   PubMed Web of Science ®Google Scholar
• Niazi M, Andersson T, Nauclér E, Naesdal J. Evaluation of bioequivalence between a single-capsule formulation of esomeprazole 40 mg and acetylsalicylic acid 325 mg and the monotherapies given separately in healthy volunteers. Int. J. Clin. Pharmacol. Ther.49(2), 169–176 (2011).
   PubMed Web of Science ®Google Scholar
• Würtz M, Grove EL, Kristensen SD, Hvas AM. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart96(5), 368–371 (2010).
   PubMed Web of Science ®Google Scholar
• Iñarrea P, Esteva F, Cornudella R, Lanas A. Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man. Scand. J. Gastroenterol.35(3), 242–246 (2000).
   PubMed Web of Science ®Google Scholar
• Ekström P, Carling L, Wetterhus S et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy – a Nordic multicentre study. Scand. J. Gastroenterol.31, 753–758 (1996).
   PubMed Web of Science ®Google Scholar
• Cullen D, Bardhan KD, Eisner M et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment. Pharmacol. Ther.12, 135–140 (1998).
   PubMed Web of Science ®Google Scholar
• Hawkey CJ, Karrasch JA, Szczepañski L et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N. Engl. J. Med.338, 727–734 (1998).
   PubMed Web of Science ®Google Scholar
• Scheiman JM, Yeomans ND, Talley NJ et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am. J. Gastroenterol.101, 701–710 (2006).
   PubMed Web of Science ®Google Scholar
• Chan FK, Ching JY, Hung LC et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N. Engl. J. Med.352(3), 238–244 (2005).
   PubMed Web of Science ®Google Scholar
• Lai KC, Chu KM, Hui WM et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complication. Clin. Gastroenterol. Hepatol.4(7), 860–865 (2006).
   PubMed Web of Science ®Google Scholar
• Lanas A, Garcia Rodriguez LA, Arroyo MT et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am. J. Gastroenterol.102, 507–515 (2007).
   PubMed Web of Science ®Google Scholar
• Okada K, Inamori M, Imajo K et al. Clinical study of upper gastrointestinal bleeding associated with low-dose aspirin in Japanese patients. Hepatogastroenterology56(96), 1665–1669 (2009).
   PubMedGoogle Scholar
• Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the Prevention of Peptic Ulcers and Oesophagitis in Patients Taking Low-dose Aspirin (FAMOUS): a Phase III, randomised, double-blind, placebo-controlled trial. Lancet374, 93–94 (2009).
   PubMedGoogle Scholar
• Ng FH, Wong SY, Lam KF et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology138, 82–88 (2010).
   PubMed Web of Science ®Google Scholar
• Laine L. GI risk and risk factors of NSAIDs. J. Cardiovasc. Pharmacol.47(Suppl. 1), S60–S66 (2006).
   Web of Science ®Google Scholar
• Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA296(24), 2947–2953 (2006).
   PubMed Web of Science ®Google Scholar
• Gray SL, LaCroix AZ, Larson J et al. Proton pump inhibitor use, hip fracture and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch. Intern. Med.170(9), 765–771 (2010).
   PubMed Web of Science ®Google Scholar
• Johnson DA. Safety of proton pump inhibitors: current evidence for osteopororis and interaction with antiplatelet agents. Curr. Gastroenterol. Rep.12(3), 167–174 (2010).
   PubMedGoogle Scholar
• Bhatt DL, Cryer BL, Contant CF et al. Clopidogrel with or without omeprazole in coronary artery disease. N. Engl. J. Med.363(20), 1909–1917 (2010).
   PubMed Web of Science ®Google Scholar
• Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am. J. Gastroenterology102, 2047–2056 (2007).
   PubMed Web of Science ®Google Scholar
• Giraud AS. The evolution of the gastric mucosa. In: PhD Thesis. The University of Melbourne, Melbourne, Australia (1980).
   Google Scholar
• Dial MS. Proton pump inhibitor use and enteric infections. Am. J. Gastroenterol.104(Suppl. 2), S10–S16 (2009).
   Web of Science ®Google Scholar
• Bhatt DL, Scheiman J, Abraham NS et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am. J. Gastroenterol.103, 2890–2907 (2008).
   PubMedGoogle Scholar
• Barkun AN, Bardou M, Kuipers EJ et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann. Intern. Med.152(2), 101–113 (2010).
   PubMed Web of Science ®Google Scholar
• Rostom A, Moayyedi P, Hunt R. Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment. Pharmacol. Ther.29(5), 481–496 (2009).
   PubMed Web of Science ®Google Scholar
• Redberg RF, Benjamin EJ, Bittner V et al. ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults. J. Am. Coll. Cardiol.54, 1364–1405 (2009).
   PubMedGoogle Scholar
• Stempel DA, Stoloff SW, Carranza Rosenzweig JR, Stanford RH, Ryskina KL, Legoretta AP. Adherence to asthma controller medication regimens. Respir. Med.99, 1263–1267 (2005).
   PubMed Web of Science ®Google Scholar
• Marceau C, Lemiere C, Berbiche D, Perreault S, Blais L. Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma. J. Allergy Clin. Immunol.118, 574–581 (2006).
   PubMed Web of Science ®Google Scholar
• Yentzer BA, Ade RA, Fountain JM et al. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis86(2), 103–108 (2010).
   PubMed Web of Science ®Google Scholar
• Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J. Am. Coll. Cardiol.45(3), 456–459 (2005).
   PubMed Web of Science ®Google Scholar
• Sung JJ, Lau JY, Ching JY et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann. Intern. Med.152(1), 1–9 (2010).
   PubMed Web of Science ®Google Scholar
• Sung JJ, Chan FK, Chen M et al. Asia–Pacific Working Group consensus on non-variceal upper gastrointestinal bleeding. Gut DOI: 10.1136/gut.2010.230292 (2011) (Epub ahead of print).
   Google Scholar
• Din FVN, Theodoraou E, Farrington SM et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut59(12), 1670–1679 (2010).
   PubMed Web of Science ®Google Scholar